… Nucleic-acid-based aptamers are developed through a process called Systematic Evolution
of Ligands by Exponential enrichment (SELEX), as outlined in Figure 1 [10,25]. SELEX …

… , nucleic acid–based therapies are a promising and potential therapeutic strategy for diseases
in which nucleic acids … and autoimmune diseases associated with Alzheimer's disease. …

… This kind of development of unknowing diseases can be tackled by targeted gene therapy.
The targeted genetic manipulation … This type of therapy is employed in cancer theranostics. …

… and targeted delivery of nucleic acids. However, their delivery remains a limiting factor for
nucleic acid-based theranostics.The classical form of nucleic acid-based therapeutics involves …

… disorders including Alzheimer's disease (AD). Administration of specific anti-Aẞ monoclonal
antibodies (aAẞmAbs) could delay the aggregation of Aẞ in the brain. In this context, the in …

… in the measurement tools suitable for cost-effective theranostics. … Nucleic acid based biosensors
are developed by im… one marker to distinguish Alzheimer's disease patients and others, …

Gene therapy has been used as a potential approach to address the diagnosis and treatment
of genetic diseases and inherited disorders. In this line, non-viral systems have been …

… These companies which are dealing with the clinical trials include mirage Therapeutics,
SantarisPharma, Mirna Therapeutics, and Regulus Therapeutics. Clinical trials of numerous …

… in the initiation, development, and theranostics of various diseases, including AD. In this …
, suggesting potential implications in the pathogenesis and theranostics of human diseases. …

… Progress made in the nucleic acid–based therapeutics has gained tremendous interest in
the inhibition of expression of α-synuclein using inhibitory genes. However, similar to AD, here …